Roche boosts drug profile with US merger

Swiss drug company Roche has announced it is buying United States-based Anadys Pharmaceuticals for $230 million ($257 million).

This content was published on October 17, 2011 and agencies

Basel-based Roche said on Monday that the merger would boost its portfolio of drugs to treat hepatitis C. Anadys has developed an oral drug called Setrobuvir that is currently being trialed for treatment of chronic hepatitis C infections.

Roche said it would pay $3.70 per share, a premium of more than 250 per cent on Anadys's closing price on Friday.

Anadys CEO Steve Worland said the merger provided “the best chance of success for the new potential treatments our team has been dedicated to developing”.

Roche is a world leader in cancer treatments, diagnostics and diabetes treatments.

In compliance with the JTI standards

In compliance with the JTI standards

More: SWI certified by the Journalism Trust Initiative

Contributions under this article have been turned off. You can find an overview of ongoing debates with our journalists here. Please join us!

If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at

Change your password

Do you really want to delete your profile?

Your subscription could not be saved. Please try again.
Almost finished... We need to confirm your email address. To complete the subscription process, please click the link in the email we just sent you.

Discover our weekly must-reads for free!

Sign up to get our top stories straight into your mailbox.

The SBC Privacy Policy provides additional information on how your data is processed.